TGFB1 and neoplasm: We now approach CDK5 and cancer from an immunotherapy angle as well, by which inhibition of the CDK5/p35 would enhance NK-cell antitumor cytotoxicity and inhibit tumor microenvironmental TGFβ-mediated NK-cell dysfunction.